Kala Pharmaceuticals Secures $11.5 Million in Series A Financing

Feb 28, 2013 · WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to …

CouponFollow Extension

$11
OFF

Kala Pharmaceuticals Secures $11.5 Million In Series A Financing

1 week from now

Feb 28, 2013 · WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to …

fiercebiotech.com

$11
OFF

Investors Cough Up $11.5M For Kala Pharmaceuticals

1 week from now

Kala Pharmaceuticals, a Waltham, MA-based developer of treatments for diseases affecting mucosal tissues, has secured $11.5 million in Series A financing. The company will use the …

pitchbook.com

$11
OFF

Kala Pharmaceuticals Secures $11.5 Million In Series A Financing

1 week from now

kalarx.com

$115
OFF

Kala Pharmaceuticals - Raised $115M Funding From 16 Investors

1 week from now

Nov 5, 2024 · Kala Pharmaceuticals has raised a total funding of $115M over 11 rounds from 16 investors. Investors include Athyrium Capital Management, Vivo Capital and 14 others. Their …

tracxn.com

$11
OFF

Kala Pharmaceuticals Secures $11.5m Series A - Venture Capital …

1 week from now

Feb 28, 2013 · Kala Pharmaceuticals has secured $11.5 million in Series A equity financing through new and existing investors. New and lead investor Crown Venture Fund the venture …

venturecapitaljournal.com

$11
OFF

Kala Pharmaceuticals Inks $11.5M In Series A - VC News Daily

1 week from now

Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat a wide range of debilitating diseases, announced today …

vcnewsdaily.com

$11
OFF

Kala Pharmaceuticals Raises $11.5M In Series A Equity Financing

1 week from now

Feb 28, 2013 · Kala Pharmaceuticals, a Waltham, MA-based developer of innovative products that treat a wide range of debilitating diseases by penetrating the mucosal barrier, raised …

finsmes.com

$31
OFF

Kala Pharmaceuticals Reports Fourth Quarter And Full Year 2022 ...

1 week from now

Mar 3, 2023 · -- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 -- -- Closed $31.0 million private placement …

yahoo.com

$115
OFF

Kala Pharmaceuticals - Raised $115M Funding From 16 Investors

1 week from now

Kala Pharmaceuticals has raised a total funding of $115M over 10 rounds from 16 investors. Investors include Polaris Partners, Orbimed and 14 others. Their latest funding round was of …

tracxn.com

$16122541
OFF

Post-IPO Equity - Kala Pharmaceuticals - 2021-11-29 - Crunchbase

1 week from now

Kala Pharmaceuticals raised $16122541 on 2021-11-29 in Post-IPO Equity. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log …

crunchbase.com

218%
OFF

Kala Pharmaceuticals: The Biotech Stock That Soared By 218% In …

1 week from now

Dec 29, 2022 · Combined with the current cash on hand, management anticipates it has enough capital to last until 1Q25.All told, Chen sticks with a Buy rating for KALA shares along with a …

nasdaq.com

750%
OFF

Kala Pharmaceuticals Stock Up 750% In 3 Days After Upbeat

1 week from now

Dec 30, 2022 · Kala’s stock is still down 44.8% year to date, while the iShares Biotechnology ETF IBB has slumped 14.9% and the S&P 500 SPX has shed 19.8%. About the Author Tomi Kilgore

marketwatch.com

$11
OFF

Kala Pharmaceuticals Has Received $11.5m In Series A Equity …

1 week from now

Kala Pharmaceuticals, a developer of products that effectively penetrate the mucosal barrier to treat various debilitating diseases, has received $11.5m in Series A equity financing round, led …

made-in-china.com

$31
OFF

Kala Pharmaceuticals Announces Up To $31 Million Private …

1 week from now

Nov 28, 2022 · Under the terms of the agreement, Kala has agreed to sell in a first tranche an aggregate of 76,813 shares of its common stock at a price of $5.75 per share and an …

yahoo.com

FAQs about Kala Pharmaceuticals Secures $11.5 Million in Series A Financing Coupon?

What happened to the Kala Pharmaceuticals Inc stock price?

The Kala Pharmaceuticals Inc stock price fell by -5.73% on the last day (Wednesday, 29th Mar 2023) from $15.72 to $14.82. The price has fallen in 6 of the last 10 days and is down by -11.2% for this period. The stock fluctuated 11.29% from a day low at $14.61 to a day high of $16.26. ...

Is Kala Pharmaceuticals Inc stock a buy or sell signal?

The Kala Pharmaceuticals Inc stock has a buy signal from the long-term moving average; however, it also holds a sell signal from the short-term moving average. Despite the short-term sell signal, the fact that the long-term average is above the short-term average indicates a general buy signal in the stock, giving a positive forecast for Kala Pharmaceuticals Inc stock. ...

What is the expected price of Kala Pharmaceuticals Inc (KLA)?

For the upcoming trading day, we expect Kala Pharmaceuticals Inc to open at $15.23. The possible trading interval, based on the 14 day Average True Range, is +/-$2.54, which gives a possible range of $12.28 to $17.36. This gives a possible trading interval of up to $5.08 or down to $3.05 from the last closing price. ...

What is the difference between Kala Pharmaceuticals Inc (Kala) and the S&P 500?

Kala Pharmaceuticals Inc (KALA) stock is lower by -4.76% while the S&P 500 is higher by 0.05% as of 2:45 PM on Tuesday, Jan 24. KALA is down -$0.84 from the previous closing price of $17.60 on volume of 203,110 shares. Over the past year the S&P 500 is lower by -8.81% while KALA is down -61.35%. ...

How much will Kala sell?

Under the terms of the agreement, Kala has agreed to sell in a first tranche an aggregate of 76,813 shares of its common stock at a price of $5.75 per share and an aggregate of 9,666 shares of its Series E Preferred at a price of $575.00 per share, for gross proceeds of approximately $6 million. ...

What happened to Kala shares?

As the major indexes took a further beating on Wednesday, KALA shares saw out the session up by 218% after the company announced that the IND (investigational new drug) application for its lead product candidate KPI-012, indicated to treat persistent corneal epithelial defect (PCED), had been accepted by the FDA. ...